3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
31
Head & Neck
1
Gynecologic
1
Genitourinary
1
Breast
1
Conditions
Breast Neoplasms
401
Triple Negative Breast Neoplasms
64
Neoplasm Metastasis
50
Neoplasms
19
Breast Neoplasms, Male
14
Colorectal Neoplasms
13
Brain Neoplasms
13
Stomach Neoplasms
11
Pancreatic Neoplasms
11
Colonic Neoplasms
7
Carcinoma, Non-Small-Cell Lung
7
Ovarian Neoplasms
6
Inflammatory Breast Neoplasms
6
HER2-positive Breast Cancer
6
Squamous Cell Carcinoma of Head and Neck
5
Parkinson Disease 4, Autosomal Dominant Lewy Body
5
Advanced Breast Cancer
5
Rectal Neoplasms
4
HER2 Positive Metastatic Breast Cancer
4
Breast Cancer Metastatic
4
Sarcoma
3
Prostatic Neoplasms
3
Meningeal Neoplasms
3
Lymphoma, Non-Hodgkin
3
Gallbladder Neoplasms
3
Esophageal Neoplasms
3
Carcinoma, Hepatocellular
3
Small Cell Lung Carcinoma
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Neoplasms, Unknown Primary
2
Interventions
pembrolizumab
9
Gemcitabine
5
Cisplatin
5
Nivolumab
3
Drug Therapy
3
budigalimab
2
Injections
2
Docetaxel
2
Carboplatin
2
zenocutuzumab
1
venetoclax
1
tislelizumab
1
spartalizumab
1
seribantumab
1
saracatinib
1
rovalpituzumab tesirine
1
pertuzumab
1
pemigatinib
1
niraparib
1
margetuximab
1
lenvatinib
1
futibatinib
1
fludarabine
1
entrectinib
1
durvalumab
1
crenigacestat
1
cediranib
1
bemarituzumab
1
anlotinib
1
anetumab ravtansine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Cholangiocarcinoma
×
Capecitabine
×
Breast
×
Clear all
NCT05007106
2025-08-14
KEYVIBE-005
Merck Sharp & Dohme LLC
Phase 2
Completed
613 enrolled